title: [Basic mechanisms of migraine and new methods of treatment].
abstract: Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.
authors.forename: Jakob Møller
authors.initials: JM
authors.lastname: Hansen
authors.affiliation: ashina@dadlnet.dk.
authors.forename: Messoud
authors.initials: M
authors.lastname: Ashina
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D014276:Trigeminal Nerve / Q000502:physiology
chemical_list: D019274:Botulinum Toxins, Type A; D015740:Calcitonin Gene-Related Peptide